For example, up to 50% of AR mutations in CRPC strains, such as residue 741 (W741C), can convert the AR antagonist bicalutamide to an activator that activates the AR and promotes tumor growth (Osguthorpe and Hagler, 2011). This evidence concerns the gene AR and neoplasm.